AcquisitionOther
Amneal Pharmaceuticals acquired Kashiv BioSciences
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Amneal Pharmaceuticals -> Kashiv BioSciences · $375 million cash plus $375 million equity, plus up to $350 million milestone payments
To establish fully integrated global biosimilars platform ahead of $300B+ biologics loss-of-exclusivity wave and capitalize on biosimilar market growth.
Open source record (SEC) ↗